Haydeh Payami

This study identifies dysbiotic gut microbiome features in Parkinson's disease, links them to genetic variants, and proposes microbiome-based biomarkers for targeted treatment.

This study conducts a genome-wide association study of copy number variations in Parkinson's disease, identifying a significant PRKN deletion but limited replication in an independent dataset.

The paper develops microbiome-based biomarkers to identify suitable patients for microbiome-based therapies in Parkinson's disease, showing that not all patients have dysbiotic microbiomes and that dysbiotic microbiomes vary in features.

This study shows that alpha-synuclein overexpression in mice alters gut microbiome composition with age, suggesting a potential link between PD pathology and microbiome dysbiosis.

This study investigates the gut microbiome's role in Parkinson's disease using metagenomics, finding widespread dysbiosis and associations with disease mechanisms.

This study identifies genetic modifiers of LRRK2 mutations in Parkinson's disease, finding a significant variant in CORO1C and a polygenic risk score effect on penetrance.

The paper shows that genetic variants at the alpha-synuclein locus influence gut microbiome dysbiosis in Parkinson's disease.

The paper identifies 31 host genetic loci influencing gut microbiome composition through GWAS and suggests causal effects in inflammatory diseases.

This study identifies three clusters of gut microbiota associated with Parkinson's disease, including overabundance of opportunistic pathogens.